STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Syndax Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Syndax Pharmaceuticals Schedule 13G/A shows that Point72-related entities and Steven A. Cohen report shared beneficial ownership of 2,307,824 shares of Syndax common stock, representing 2.7% of the class as of the close of business on June 30, 2025. The filing states Point72 Asset Management exercises shared voting and dispositive power over these shares on behalf of an investment fund it manages; Point72 Capital Advisors is the general partner and Mr. Cohen controls both entities. The filing clarifies the position is not intended to indicate an attempt to influence control of the issuer.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Point72 group reports a modest 2.7% shared stake in Syndax, non-controlling and below 5% disclosure thresholds.

The reported 2,307,824 shares equal 2.7% of Syndax and are held through an investment fund managed by Point72 Asset Management. For investors, this is a disclosure of a minority economic interest with shared voting and dispositive power, not a control transaction. The filing is routine under Schedule 13G/A for passive or qualifying investors and contains no operational data, transactions, or changes to Syndax's business or governance. Impact on valuation or strategy is likely minimal given the sub-5% stake.

TL;DR: Ownership is shared and disclosed properly; the filing expressly denies intent to influence control.

The statement documents that Point72 Asset Management holds investment and voting power via an investment management agreement, with Point72 Capital Advisors as general partner and Steven A. Cohen as controller. The certification affirms the securities were not acquired to change or influence issuer control. This aligns with routine governance disclosure practices and raises no immediate governance or activist concerns based on the information provided.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:08/14/2025
Syndax Pharmaceuticals Inc

NASDAQ:SNDX

SNDX Rankings

SNDX Latest News

SNDX Latest SEC Filings

SNDX Stock Data

1.77B
85.79M
1.29%
120.98%
24.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK